GNCA Projected Dividend Yield

Genocea Biosciences Inc ( NASDAQ : GNCA )

Genocea Biosciences is a biopharmaceutical company that discovers and develops cancer immunotherapies using its ATLAS™ platform. The ATLAS platform profiles each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by sequencing of that patient's tumor. Co.'s GEN-011 program is an adoptive T cell therapy using neoantigen-targeted peripheral cells (NPTs). The GEN-011 NPTs are specific for ATLAS identified anti-tumor antigens that are used to manufacture peripheral blood-derived, tumor-specific T cell therapy. Co.'s GEN-009 program is a neoantigen vaccine delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens.

20 YEAR PERFORMANCE RESULTS